Scientists at the Department of Cancer Research (DoCR) at the Luxembourg Institute of Health (LIH) have revealed the ground-breaking therapeutic potential of the compound FL3 in inhibiting oncogene translation and rewiring cancer cell metabolism, offering new hope for patients with chronic lymphocytic leukaemia (CLL), a prevalent form of cancer characterised by the overproduction and accumulation of dysfunctional B lymphocytes in various parts of the body. Click to read more.
Cutting-edge research at the Luxembourg Institute of Health reveals the ground-breaking therapeutic potential of the compound FL3 in inhibiting oncogene translation and rewiring cancer cell metabolism, opening up new therapeutic opportunities for leukemia patients.
COVID-19 disease severity seems to be affected by the characteristics of white blood cells called granulocytes, which are part of the innate immune system.
Date Time
Anticancer drug may improve outcome for severe COVID-19 patients
Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China that was led by researchers at Karolinska Institutet in Sweden between February and April 2020. On average, blood oxygen levels, body temperature and inflammatory markers significantly improved in patients treated with a single dose of bevacizumab in addition to standard care. The research is published in Nature Communications.
Yihai Cao, photo: Ulf Sirborn
“To reduce COVID-19 mortality, we aim to develop an effective therapeutic paradigm for treating patients with severe COVID-19,” says corresponding author Yihai Cao, professor of vascular biology at the Department of Microbiology, Tumor and Cell Biology at Karolinska Institutet. “Our findings suggest that bevacizumab plus standard care is highly beneficial for patients with severe